Haichen Pharmaceutical Obtained the Drug Registration Approval for Rivaroxaban Tablet

Haichen Pharmaceutical obtained the drug registration approval for Rivaroxaban tablet, which is a novel oral anticoagulant with advantages such as rapid onset of action, predictable efficacy, low incidence of intracranial hemorrhage, and no need for routine coagulation monitoring and routine dosage adjustment.